|
Fibrosis, Liver
|
0.400 |
Biomarker
|
disease |
BEFREE |
The importance of both NRF2 and p62-dependent autophagy in SPD-mediated liver protection was confirmed using a carbon tetrachloride-induced liver fibrosis model in wild-type, Nrf2<sup>-/-</sup> , p62<sup>-/-</sup> and Nrf2<sup>-/-</sup> ;p62<sup>-/-</sup> mice, as the protective effect of SPD was significantly reduced in NRF2 or p62 single knockout mice, and completely abolished in the double knockout mice.
|
30873635 |
2019 |
|
Fibrosis, Liver
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The hepatic expression of NFE2L2 was significantly lower in patients with advanced liver fibrosis (p = 0.05).
|
30929321 |
2019 |
|
Fibrosis, Liver
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Our results showed that TP supplementation alleviated liver morphology, liver function and liver fibrosis; improved oxidative stress parameters; and increased the expression of STAT5b, Nrf2, HO-1 and NQO-1 and decreased the expression of Keap1 in the liver tissues of aged rats.
|
31819135 |
2019 |
|
Fibrosis, Liver
|
0.400 |
Biomarker
|
disease |
BEFREE |
Asiatic acid ameliorates CCl<sub>4</sub>-induced liver fibrosis in rats: involvement of Nrf2/ARE, NF-κB/IκBα, and JAK1/STAT3 signaling pathways.
|
30464391 |
2018 |
|
Fibrosis, Liver
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
EDQ treatment significantly inhibited the expression of α-SMA, TIMP-1, COX-2, TNF-α, iNOS and increased the levels of Nrf2 in rat liver fibrosis.
|
29174446 |
2018 |
|
Fibrosis, Liver
|
0.400 |
Biomarker
|
disease |
BEFREE |
In summary, Nrf2 is critically involved in preventing liver fibrosis induced by long-term administration of APAP in mice, and Andro alleviates APAP-induced liver fibrosis by attenuating liver oxidative stress injury via inducing Nrf2 activation.
|
29355602 |
2018 |
|
Fibrosis, Liver
|
0.400 |
Biomarker
|
disease |
BEFREE |
Tanshinol ameliorates CCl<sub>4</sub>-induced liver fibrosis in rats through the regulation of Nrf2/HO-1 and NF-κB/IκBα signaling pathway.
|
29844659 |
2018 |
|
Fibrosis, Liver
|
0.400 |
Biomarker
|
disease |
BEFREE |
Taken together, activation of I<sub>1</sub>R negatively regulates the progression of liver fibrosis in the Nrf2-dependent pathway, which suggests that specifically targeting I<sub>1</sub>R may be a potential therapeutic strategy for the treatment of liver fibrosis.
|
28437886 |
2017 |
|
Fibrosis, Liver
|
0.400 |
Biomarker
|
disease |
BEFREE |
The aim of the present study was to investigate the effect of XCHT on liver fibrosis and focuse on the Nrf2 pathway in the protection of XCHT against CCl<sub>4</sub>-induced oxidative stress.
|
29078262 |
2017 |
|
Fibrosis, Liver
|
0.400 |
Biomarker
|
disease |
BEFREE |
In in vivo system, Nrf2 knockdown mediated by Nrf2 shRNA lentivirus not only accelerated the lipid degradation in HSCs but also promoted the progression of CCl<sub>4</sub>-induced hepatic fibrosis in mice.
|
28826090 |
2017 |
|
Fibrosis, Liver
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In this study, we found that the expression and activity of nuclear factor (erythroid-derived 2) - like 2 (Nrf2) were decreased in activated HSCs and negatively correlated with hepatic fibrosis severity in human liver specimens.
|
28601022 |
2017 |
|
Fibrosis, Liver
|
0.400 |
Biomarker
|
disease |
BEFREE |
Imidazoline I2 receptor inhibitor idazoxan regulates the progression of hepatic fibrosis via Akt-Nrf2-Smad2/3 signaling pathway.
|
28423499 |
2017 |
|
Fibrosis, Liver
|
0.400 |
Biomarker
|
disease |
BEFREE |
Pro-fibrotic compounds induce stellate cell activation, ECM-remodelling and Nrf2 activation in a human 3D-multicellular model of liver fibrosis.
|
28665955 |
2017 |
|
Fibrosis, Liver
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Morin enhances hepatic Nrf2 expression in a liver fibrosis rat model.
|
29307993 |
2017 |
|
Fibrosis, Liver
|
0.400 |
Biomarker
|
disease |
BEFREE |
This study demonstrates that Sch B prevents the progression of liver fibrosis by the regulation of Nrf2-ARE and TGF-β/Smad signaling pathways, and indicates that Sch B can be used for the treatment of liver fibrosis.
|
28794616 |
2017 |
|
Fibrosis, Liver
|
0.400 |
Biomarker
|
disease |
BEFREE |
Genetic disruption of NRF2 promotes the development of necroinflammation and liver fibrosis in a mouse model of HFE-hereditary hemochromatosis.
|
27936457 |
2017 |
|
Fibrosis, Liver
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Hyperoside increased the activity of the antioxidant and phase II detoxifying enzymes through the activation of Nrf2 nuclear translocated in the CCl<sub>4</sub>-induced liver fibrosis mice.
|
28434817 |
2017 |
|
Fibrosis, Liver
|
0.400 |
Biomarker
|
disease |
BEFREE |
More importantly, this genomic analysis of nano-TiO2 treated HepG2 cells linked some of the in vitro canonical pathways to in vivo adverse outcomes: NRF2-mediated response pathways to oxidative stress, acute phase response to inflammation, cholesterol biosynthesis to steroid hormones alteration, fatty acid metabolism changes to lipid homeostasis alteration, G2/M cell checkpoint regulation to apoptosis, and hepatic fibrosis/stellate cell activation to liver fibrosis.
|
26918567 |
2016 |
|
Fibrosis, Liver
|
0.400 |
Biomarker
|
disease |
BEFREE |
Nrf2 knockdown attenuates the ameliorative effects of ligustrazine on hepatic fibrosis by targeting hepatic stellate cell transdifferentiation.
|
27477297 |
2016 |
|
Fibrosis, Liver
|
0.400 |
Biomarker
|
disease |
BEFREE |
Cirrhotic rats treated with simvastatin or Ad-KLF2 showed hepatic upregulation in the KLF2-Nrf2 pathway, deactivation of HSC and prominent reduction in liver fibrosis.
|
25500203 |
2015 |
|
Fibrosis, Liver
|
0.400 |
Biomarker
|
disease |
BEFREE |
This strategy of Nrf2 activation presents new opportunities for treatment of NASH patients with hepatic fibrosis.
|
23592516 |
2013 |
|
Fibrosis, Liver
|
0.400 |
Therapeutic
|
disease |
CTD_human |
We also show that Nrf2 may reveal significant gene expression changes, suggesting that Nrf2 activation may ameliorate liver fibrosis.
|
23793039 |
2013 |
|
Fibrosis, Liver
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We also show that Nrf2 may reveal significant gene expression changes, suggesting that Nrf2 activation may ameliorate liver fibrosis.
|
23793039 |
2013 |
|
Fibrosis, Liver
|
0.400 |
Biomarker
|
disease |
BEFREE |
Collectively, these results show that SFN elicits an antifibrotic effect on hepatic fibrosis through Nrf2-mediated inhibition of the TGF-β/Smad signaling and subsequent suppression of HSC activation and fibrogenic gene expression.
|
22155056 |
2012 |
|
Fibrosis, Liver
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Effects of blueberry on hepatic fibrosis and transcription factor Nrf2 in rats.
|
20518088 |
2010 |